Patent details

301031 Product Name: Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301031
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2371361
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
301031
Procedural language:
Dutch
First Applicant Residence Country:
Netherlands (NL)

Marketing Authorization

Marketing Authorization Number:
EU/1/09/537/001
Marketing Authorization Type:
EEA
Marketing Authorization Date:
04/08/2009
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
22/01/2020
First Marketing Authorization date:
04/08/2009
Grant date:
20/07/2020
Activation date:
30/07/2022
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
31/01/2020
SPC/SPC Extension Expiration Date:
03/08/2024
Lapsed By Expiration Date:
04/08/2024
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
22/05/2023
 
 

 

Name:
Sanofi B.V.
Address:
Paasheuvelweg 25, 1105 BP, Amsterdam, Netherlands (NL)

Historical Applicant/holder

From:
22/01/2020
To:
22/05/2023

 

Name:
GENZYME EUROPE B.V.
Address:
Paasheuvelweg 25, 1105 BP, Amsterdam, Netherlands (NL)

Agent

Name:
ir. H.A. Witmans c.s.
From:
22/01/2020
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
32/24
Publication date:
07/08/2024
Description:
Lapse or annulment

2

Bulletin Heading:
CO
Journal edition number:
23/23
Publication date:
07/06/2023
Description:
Changes in the Netherlands Patent Register

3

Bulletin Heading:
SPC
Journal edition number:
31/22
Publication date:
03/08/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

4

Bulletin Heading:
SPC
Journal edition number:
30/20
Publication date:
22/07/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

5

Bulletin Heading:
SPC
Journal edition number:
06/20
Publication date:
05/02/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Change of owner(s) name
Deed Number:
RC202301018A
Date Registered:
22/05/2023
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. H.A. Witmans c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
Sanofi B.V.
Address:
Paasheuvelweg 25, 1105 BP, Amsterdam, Netherlands (NL)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
16/07/2024
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
2000 Euro
Payer:
Arnold & Siedsma BV
Filing date Document type Document Description Number of pages File Type
21/07/2020 Front Page Front Page 1 PDF /7/6/7/1/1/0800511767/docs/301031_9_i2frontpage20200721101534554.pdf
20/07/2020 SPC Documents Certificate SPC 1 PDF /7/6/7/1/1/0800511767/docs/301031_12_supplprotectioncertificate20200721095142703.pdf
20/07/2020 Outgoing Correspondence Decision grant 3 PDF /7/6/7/1/1/0800511767/docs/301031_15_355202l504a.pdf
16/07/2020 Outgoing Correspondence Confirmation receipt communication third party 1 PDF /7/6/7/1/1/0800511767/docs/301031_0_354781l037.pdf
16/07/2020 Outgoing Correspondence Letter communication third party to holder 1 PDF /7/6/7/1/1/0800511767/docs/301031_14_354763l035.pdf
15/07/2020 SPC Documents Annex third party observations SPC 5 PDF /7/6/7/1/1/0800511767/docs/301031_3_supplprotectioncertificate20200716105403705.pdf
15/07/2020 SPC Documents Third party observations SPC 6 PDF /7/6/7/1/1/0800511767/docs/301031_4_supplprotectioncertificate20200716105630900.pdf
15/07/2020 SPC Documents Annex third party observations SPC 294 PDF /7/6/7/1/1/0800511767/docs/301031_17_supplprotectioncertificate20200716110243834.pdf
03/02/2020 Front Page Front Page 1 PDF /7/6/7/1/1/0800511767/docs/301031_2_i1frontpage20200203104459172.pdf
03/02/2020 Outgoing Correspondence Confirmation receipt request 1 PDF /7/6/7/1/1/0800511767/docs/301031_16_323513l174.pdf
22/01/2020 SPC Documents Annex SPC 1 PDF /7/6/7/1/1/0800511767/docs/301031_1_supplprotectioncertificate20200131125444035.pdf
22/01/2020 SPC Documents Summary of the characteristics of the product 12 PDF /7/6/7/1/1/0800511767/docs/301031_5_supplprotectioncertificate20200131125443685.pdf
22/01/2020 SPC Documents Annex SPC 11 PDF /7/6/7/1/1/0800511767/docs/301031_6_supplprotectioncertificate20200131125443856.pdf
22/01/2020 Application Form First filed application form 3 PDF /7/6/7/1/1/0800511767/docs/301031_7_applicationform20200131125443288.pdf
22/01/2020 SPC Documents Marketing Authorization SPC 3 PDF /7/6/7/1/1/0800511767/docs/301031_8_supplprotectioncertificate20200131125443604.pdf
22/01/2020 SPC Documents Annex SPC 1 PDF /7/6/7/1/1/0800511767/docs/301031_10_supplprotectioncertificate20200131125443958.pdf
22/01/2020 SPC Documents Annex SPC 2 PDF /7/6/7/1/1/0800511767/docs/301031_11_supplprotectioncertificate20200131125443761.pdf
22/01/2020 SPC Documents Annex SPC 3 PDF /7/6/7/1/1/0800511767/docs/301031_13_supplprotectioncertificate20200131125443508.pdf